Switching multiple sclerosis treatment to ofatumumab and antibody levels
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at what happens to infection-fighting antibody levels when people with relapsing multiple sclerosis switch from ocrelizumab to ofatumumab. It may help doctors understand if switching is a good option for people whose antibody levels are low.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been on ocrelizumab for at least 18 months for relapsing multiple sclerosis.
- Your immunoglobulin levels (a type of protein that helps fight infections) have been low on two blood tests about 6 months apart.
- You have already switched, or are switching to, ofatumumab (this decision is made independently of the study).
- You agree to take part and can provide your consent.
- You have not had immunoglobulin supplementation in the last 18 months, and you are not pregnant or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
This study tests whether switching from ocrelizumab to a similar drug, ublituximab, can help people with MS who experience 'wearing-off' symptoms before their next infusion. It may offer a new option to keep symptoms more stable between doses.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study looks at how ofatumumab (Kesimpta) affects the back of the eye (retina) and certain nerve proteins in the blood in people with relapsing multiple sclerosis. It may help doctors understand how well the medication is protecting the eyes and nerves.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.